The significant up-regulation of ROCK1 in cancers harboring the TMPRSS2:ERG fusion fits with an earlier report describing increased expression of ROCK’s upstream regulator Rho guanine diphosphate dissociation inhibitor beta (ARHGDIB) in ERG positive prostate cancers [30]. Here, ERG is linked to prostate cancer.